USE OF TUMOR NECROSIS FACTOR-A INHIBITORS IN RHEUMATOID ARTHRITIS: TOPICAL ASPECTS
The use of tumor necrosis factor (TNF) а inhibitors in combination with methotrexate remains the basic method for treating active rheumatoid arthritis (RA). This line in antirheumatic therapy is rapidly developing. A number of unsolved issues associated with the selection of patients (particularly a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2008-12-01
|
| Series: | Современная ревматология |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/192 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The use of tumor necrosis factor (TNF) а inhibitors in combination with methotrexate remains the basic method for treating active rheumatoid arthritis (RA). This line in antirheumatic therapy is rapidly developing. A number of unsolved issues associated with the selection of patients (particularly at the early stage of RA) to be treated with TNF а antagonists, the prediction of its efficiency, the study of comparative aspects of therapy are on the agenda. The Russia's emergence of the latest TNF а inhibitor adalimumab that has unquestioned merits opens new vistas for the treatment of RA. |
|---|---|
| ISSN: | 1996-7012 2310-158X |